Zero-Tariff Pharma Deal Signals Major Boost for UK Life Sciences
2 December 2025
A new zero-tariff pharmaceuticals agreement between the UK and the United States is set to deliver a significant boost for UK life-sciences manufacturers, contract developers, and MedTech exporters. Under the deal, the US will grant full tariff-free access for UK-origin pharmaceuticals, active ingredients and a wide range of medical technologies for an initial three-year period, with scope for extension as regulatory cooperation deepens.
For exporters, the removal of U.S. import duties provides an immediate competitive advantage. UK-made finished medicines, biologics, advanced therapies, diagnostics equipment and medical devices will be able to enter the US market with zero border duties, reducing landed costs and improving price positioning against global competitors. This also helps UK firms compete more effectively against suppliers from countries still affected by US sector tariffs or broader trade measures.
The deal is expected to encourage greater investment in UK manufacturing, especially for high-value pharmaceutical formulations, sterile products, biotech materials, and medical device components where the UK already holds strong market credibility. Companies operating in areas such as oncology, rare-disease therapies, vaccines, cell and gene therapy, wound-care technologies, and precision medical devices may see new opportunities to expand supply contracts with US distributors and hospitals.
SMEs in the life-sciences supply chain—such as producers of APIs, excipients, packaging, diagnostics consumables and high-tech manufacturing equipment—stand to benefit as well. With tariff-free access, many smaller exporters can compete for US buyers who previously avoided UK suppliers due to duty costs or sourcing preferences linked to tariff structures.
The agreement also removes uncertainty for UK exporters at a time when several global markets are facing tariff fluctuations. Clear, predictable access to the world’s largest healthcare market enables firms to plan production volumes, secure long-term contracts, and build stronger US partnerships. For UK MedTech firms, the deal could accelerate approvals and distribution under mutual recognition pathways, reducing time-to-market and supporting faster commercialisation.
Overall, the tariff-free framework offers UK exporters a valuable window to scale their presence in the US market, enhance supply chain resilience, and attract inward investment into the UK’s world-leading life-sciences sector.
By Carla Assunção, Chamber International
We help you trade smarter, faster, and with confidence. Contact us today for expert guidance on your export and import challenges.
Follow Chamber International on Twitter @ChamberInt and on LinkedIn for the latest in international trade.
